Platelet transfusion - The art and science of compromise

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 3, 2013, Pages 160-171

  Cid, Joan ^a   Harm, Sarah K ^b   Yazer, Mark H ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

Author keywords

ABO; Alloimmunization; Antibody; Hemolysis; Mismatch; Platelets; Rh

Indexed keywords

RHESUS D ANTIBODY; RHESUS D ANTIGEN;

ALLOIMMUNIZATION; BLEEDING; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; ERYTHROCYTE; ERYTHROCYTE COUNT; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

EID: 84879364700     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000351230     Document Type: Review

References (111)

1. Dunbar NM, Ornstein DL, Dumont LJ: ABO incompatible platelets: risks versus benefit. Curr Opin He-matol 2012;19:475-479.
2. Menis M, Izurieta HS, Anderson SA, Kropp G, Hoi-ness L, Gibbs J, Erten T, Worrall CM, MaCurdy TE, Kelman JA, Ball R: Outpatient transfusions and occurrence of serious noninfectious trans fusion-related complications among US elderly, 2007-2008: utility of large administrative databases in blood safety research. Transfusion 2012;52:1968-1976.
3. Josephson CD, Mullis NC, Van Demark C, Hillyer CD: Significant numbers of apheresis-derived group 0 platelet units have high-titer anti-A/A, B: implications for transfusion policy. Transfusion 2004;44: 805-808.
4. Cooling LL, Downs TA, Butch SH, Davenport RD: Anti-A and anti-B titers in pooled group 0 platelets are comparable to apheresis platelets. Transfusion 2008;48:2106-2113.
5. Karafin MS, Blagg L, Tobian AA, King KE, Ness PM, Savage WJ: ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012;52:2087-2093.
6. Quillen K, Sheldon SL, Daniel-Johnson JA, Lee-Stroka AH, Flegel WA: A practical strategy to reduce the risk of passive hemolysis by screening plateletpher-esis donors for high-titer ABO antibodies. Transfusion 2011;51:92-96.
7. Garratty G: Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol 1998;109:769-777.
8. Cooling L: ABO and platelet transfusion therapy. Im-munohematology 2007;23:20-33.
9. Josephson CD, Castillejo MI, Grima K, Hillyer CD: ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sei 2010;42: 83-88.
10. Fung MK, Dowries KA, Shulman IA: Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med 2007;131:909-916.
11. Fauzie D, Shirey RS, Thoman S, Bensen-Kennedy D, King KE: The risk of hemolytic transfusion reactions due to passively-acquired ABO antibodies: a retrospective study of non-group 0 adult recipients of group 0 plateletpheresis transfusions [abstract], Transfusion 2004;44[suppl):36A.
12. Daniel-Johnson J, Leitman S, Klein H, Alter H, Lee-Stroka A, Scheinberg P, Pantin J, Quillen K: Probi-otic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009;49:1845-1849.
13. Consensus Conference: Platelet transfusion therapy. JAMA 1987;257:1777-1780.
14. Price T: Standards for Blood Banks and Transfusion Services. 26th ed. Bethesda, AABB, 2009.
15. Guidelines for the use of platelet transfusions. Br ] Haematol 2003;122:10-23.
16. Lozano M, Heddle N, Williamson LM, Wang G, AuBu-chon JP, Dumont LJ: Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey. Transfusion 2010;50: 1743-1748.
17. Schoenfeld H, Muhm M, Doepfmer U, Exadaktylos A, Radtke H: Platelet activity in washed platelet concentrates. AnesthAnalg 2004;99:17-20.
18. Tynngard N, Trinks M, Berlin G: Platelet quality after washing: the effect of storage time before washing. Transfusion 2010;50:2745-2752.
19. Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottier-Fox M, Pesek G, Theus J, Nakagawa M: A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion 2011;51: 1030-1036.
20. Moroff G, Friedman A, Robkin-Kline L, Gautier G, Luban NL: Reduction of the volume of stored platelet concentrates for use in neonatal patients. Transfusion 1984;24:144-146.
21. Simon TL, Sierra ER: Concentration of platelet units into small volumes. Transfusion 1984;24:173-175.
22. Roback JD: Technical Manual. 17th ed. Bethesda, AABB, 2011.
23. Fontaine MJ, Mills AM, Weiss S, Hong WJ, Viele M, Goodnough LT: How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products. Transfusion 2012;52:2081-2085.
24. Sadani DT, Urbaniak SJ, Bruce M, Tighe JE: Repeat ABO-incompatible platelet transfusions leading to haemolytic transfusion reaction. Transfus Med 2006;16:375-379.
25. High Titre Anti-A/B Testing of Donors within the National Blood Service (NBS). 2006. http://hospital bIood.co.uk/Iibrary/cIinicaI-guideIines-and-pohcies- from-nhsbt/index.asp (last accessed August 23, 2012).
26. Heal JM, Masel D, Rowe JM, Blumberg N: Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993;85:566-572.
27. Sweeney J, Kouttab N, Holme S, Cheves T, Nelson E: In vitro evaluation of presto rage pools consisting of mixed A and 0 platelet concentrates. Transfusion 2007;47:1154-1161.
28. Romphruk AV, Cheunta S, Pakoate L, Kumpeera P, Sripara P, Paupairoj C, Romphruk A: Preparation of single donor platelet with low antibody titers for all patients. Transfus Apher Sri 2012;46:125-128.
29. Perseghin P: High concentration plasma-reduced plateletapheresis concentrates. Transfus Apher Sri 2011;44:273-276.
30. Alhumaidan H, Sweeney J: Current status of additive solutions for platelets. J Clin Apher 2012;27:93-98.
31. Ringwald J, Zimmermann R, Eckstein R: The new generation of platelet additive solution for storage at 22 degrees C: development and current experience. Transfus Med Rev 2006;20:158-164.
32. Gulliksson H: Additive solutions for the storage of platelets for transfusion. Transfus Med 2000;10: 257-264.
33. Ogasawara K, Ueki J, Takenaka M, Furihata K: Study on the expression of ABH antigens on platelets. Blood 1993;82:993-999.
34. Cooling LL, Kelly K, Barton J, Hwang D, Koerner TA, 3 Olson JD: Determinants of ABH expression on human blood platelets. Blood 2005;105:3356-3364.
35. Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH: Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000;96:1574-1581.
36. Curtis BR, Aster RH: Expression of ABH antigens on platelets. Blood 2006;107:842; author reply 843.
37. Sant'Anna Gomes BM, Estalote AC, Palatnik M, Pi-menta G, Pereira Bde B, Do Nascimento EM: Prevalence, serologic and genetic studies of high expressers of the blood group A antigen on platelets∗. Transfus Med 2010;20:303-314.
38. DeLelys ME, Ochoa G, Cserti-Gazdewich CM, Vietz CM, Preffer FI, Dzik WH: Relationship between ABH genotype and A antigen expression on platelets. Transfusion 2012;doi: lO.llll/j.1537-2995.2012.03952.x..
39. Klumpp TR, Herman JH, Innis S, Pearlman E, Culling N, Kotz KW, Slachta C, Goldberg SL, Mangan KF: Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996;17:1035-1041.
40. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet increments, platelet refrac- 4toriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
41. Heal JM, Blumberg N, Masel D: An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987;70: 23-30.
42. Tosato G, Applebaum FR, Deisseroth AB: HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 1978;52:846-854.
43. van Eys J, Thomas D, Olivos B: Platelet use in pediatric oncology: a review of 393 transfusions. Transfusion 1978;18:169-173.
44. Pavenski K, Warkentin TE, Shen H, Liu Y, Heddle NM: Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Transfusion 2010;50:1552-1560.
45. Julmy F, Ammann RA, Taleghani BM, Fontana S, Hirt A, Leibundgut K: Transfusion efficacy of ABO major-mismatched platelets [PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009;49: 21-33.
46. Lin Y, Callum JL, Coovadia AS, Murphy PM: Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion 2002;42:166-172.
47. Shehata N, Tinmouth A, Naglie G, Freedman J, Wilson K: ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009; 49:2442-2453.
48. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-613.
49. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, Granger S, Slichter SJ: The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012;119:5553-5562.
50. Heal JM, Blumberg N, Kirkley SA, DiPersio JF, Rap-oport AP, Rowe JM: Leukocyte-reduced transfusions of ABO-identical platelets and clinical outcome in autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1994;14:943-948.
51. Shanwell A, Ringden O, Wiechel B, Rumin S, Akerblom 0: A study of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991;60:23-27.
52. Blumberg N, Heal JM, Liesveld JL, Phillips GL, Rowe JM: Platelet transfusion and survival in adults with acute leukemia. Leukemia 2008;22:631-635.
53. Lapierre V, Mahe C, Auperin A, Stambouli F, Oubouzar N, Tramalloni D, Benhamou E, Tiberghien P, Hartmann 0: Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005;80:314-319.
54. Heal JM, Kenmotsu N, Rowe JM, Blumberg N: A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994;45:189-190.
55. Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N: The role of ABO matching in platelet transfusion. Eur J Haematol 1993;50:110-117.
56. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW: Transfusion of ABO-mis matched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75:408-413.
57. Refaai MA, Fialkow LB, Heal JM, Henrichs KF, Spinelli SL, Phipps RP, Masel E, Smith BH, Corsetti JP, Francis CW, Bankey PE, Blumberg N: An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang 2011;101:55-60.
58. Blumberg N, Heal JM, Hicks GL Jr, Risher WH: Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 2001;41:790-793.
59. Yazer MH, Raval JS, Triulzi DJ, Blumberg N: ABO-mismatched transfusions are not over-represented in febrile non-haemolytic transfusion reactions to platelets. Vox Sang 2012;102:175-177.
60. Henrichs KF, Howk N, Masel DS, Thayer M, Refaai MA, Kirkley SA, Heal JM, Blumberg N: Providing ABO-identical platelets and cryoprecipitate to [almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence. Transfusion 2012;52:635-640.
61. Refaai MA, Carter J, Henrichs KF, Davidson DC, Pollock SJ, Casey AE, Spinelli SL, Phipps RP, Francis CW, Blumberg N: Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B. Transfusion 2012;53:382-393.
62. Zimring JC, Hendrickson JE: The role of inflammation in alloimmunization to antigens on transfused red blood cells. Curr Opin Hematol 2008;15:631-635.
63. Zimring JC: Recent developments and future directions of alloimmunization to transfused blood products. Clin Lab Med 2010;30:467-473.
64. Shanwell A, Andersson TM, Rostgaard K, Edgren G, Hjalgrim H, Norda R, Melbye M, Nyren O, Reilly M: Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang 2009;96:316-323.
65. Inaba K, Branco BC, Rhee P, Holcomb JB, Black-bourne LH, Shulman I, Nelson J, Demetriades D: Impact of ABO-identical vs ABO-compatible nonidenti-cal plasma transfusion in trauma patients. Arch Surg 2010;145:899-906.
66. Dunstan RA, Simpson MB, Rosse WF: Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 1984;24:243-246.
67. British Committee for Standards in Haematology, Blood Transfusion Task Force: Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122:10-23.
68. Cid J, Lozano M: Risk of Rh[D) alloimmunization after transfusion of platelets from D+ donors to D-recipients. Transfusion 2005;45:453; author reply 454.
69. Lozano M, Estebanell E, Cid J, Diaz-Ricart M, Maz-zara R, Ordinas A, Escolar G: Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion 1999;39: 951-959.
70. Kitazawa J, Nollet K, Morioka H, Tanaka K, Inomata M, Kubuki Y, Ohto H: Non-D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles? Vox Sang 2011;100: 395-400.
71. Greenwalt TJ: The how and why of exocytic vesicles. Transfusion 2006;46:143-152.
72. Oreskovic RT, Dumaswala UJ, Greenwalt TJ: Expression of blood group antigens on red cell microvesi-cles. Transfusion 1992;32:848-849.
73. Cook K, Rush B: Rh[D) immunization after massive transfusion of Rh[D)-positive blood. Med J Aust 1974;1:166-168.
74. Bowman HS: Effectiveness of prophylactic Rh immunosuppression after transfusion with D-positive blood. Am J Obstet Gynecol 1976;124:80-84.
75. Urbaniak SJ, Robertson AE: A successful program of immunizing Rh-negative male volunteers for anti-D production using frozen/thawed blood. Transfusion 1981;21:64-69.
76. Young NT, Street J, Darke C: Immunoglobulin allotype frequencies in responders and nonresponders to the Rh[D) antigen. Exp Clin Immunogenet 1995; 12:88-91.
77. The Rh blood group system [and LW); in Harvey G. Klein HG, Anstee DJ [eds): Mollison's Blood Transfusion in Clinical Medicine, 11 ed. Maiden, Blackwell, 2005, pp 163-208.
78. Gunson HH, Stratton F, Cooper DG, Rawlinson VI: Primary immunization of Rh-negative volunteers. Br Med J [Clin Res Ed) 1970;1:593-595.
79. Pollack W, Ascari WQ, Crispen JF, O'Connor RR, Ho TY: Studies on Rh prophylaxis. II. Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion 1971;11: 340-344.
80. Archer GT, Cooke BR, Mitchell K, Parry P: Hyper-immunization of blood donors for the production of anti-Rh [D) gamma globulin [in French). Rev Fr Transfus 1969;12:341-350.
81. Contreras M, Mollison PL: Failure to augment primary Rh immunization using a small dose of passive IgG anti-Rh. Br J Haematol 1981;49:371-381.
82. Gunson HH, Stratton F, Phillips PK: The use of modified cells to induce an anti-Rh response. Br J Haematol 1971;21:683-694.
83. Goldfinger D, McGinniss MH: Rh-incompatible platelet transfusions-risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971; 284:942-944.
84. Lichtiger B, Surgeon J, Rhorer S: Rh-incompatible platelet transfusion therapy in cancer patients. A study of 30 cases. Vox Sang 1983;45:139-143.
85. Heim MU, Schleuning M, Eckstein R, Huhn D, Siegert W, Clemm C, Ledderose G, Kolb HJ, Wilmanns W, Mempel W: Rh antibodies against the pretransplant red cells following Rh-incompatible bone marrow transplantation. Transfusion 1988;28:272-275.
86. Atoyebi W, Mundy N, Croxton T, Littlewood TJ, Murphy MF: Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? Br J Haematol 2000;111:980-983.
87. Molnar R, Johnson R, Sweat LT, Geiger TL: Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion 2002;42:177-182.
88. Baldwin ML, Ness PM, Scott D, Braine H, Kickler TS: Alloimmunization to D antigen and HLA in D-nega-tive immunosuppressed oncology patients. Transfusion 1988;28:330-333.
89. McLeod BC, Piehl MR, Sassetti RJ: Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990;59: 185-189.
90. Bartley AN, Carpenter JB, Berg MP: D+ platelet transfusions in D- patients: cause for concern? Im-munohematology 2009;25:5-8.
91. Cid J, Ortin X, Elies E, Castella D, Panades M, Martin-Vega C: Absence of anti-D alloimmunization in hematologic patients after D-incompatible platelet transfusions. Transfusion 2002;42:173-176.
92. Cid J: PLT transfusions from D+ blood donors to D-patients with hematologic diseases: an update. Transfusion 2003;43:1759-1760.
93. Misso S, Feola B, L. P, DOnofrio M, Fratellanza G: Anti-D alloimmunisation following Rh-incompatible platelet transfusions. Blood Transfus 2006;4:102-105.
94. Zeiler T, Wittmann G, Zingsem J, Weisbach V, Zimmermann R, Eckstein R: A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of RhD immunisation after RhD-incompati-ble single donor platelet transfusion. Vox Sang 1994;66:243.
95. Cid J, Carbasse G, Pereira A, Sanz C, Mazzara R, Escolar G, Lozano M: Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients. Transfusion 2011;51:1163-1169.
96. Lozano M, Cid J: The clinical implications of platelet transfusions associated with ABO or Rh[D) incompatibility. Transfus Med Rev 2003;17:57-68.
97. Davidsohn I, Masaitis L, Stern K: Experimental studies on Rh immunization. Am J Clin Pathol 1956;26:833-843.
98. Stern K, Goodman HS, Berger M: Experimental studies on Rh immunization. Am J Clin Pathol 1961;87:189-198.
99. Menitove JE: Immuno prophylaxis for D- patients receiving platelet transfusions from D+ [correction of D-] donors? Transfusion 2002;42:136-138.
100. Ramsey G, Hahn LF, Cornell FW, Boczkowski DJ, Staschak S, Clark R, Hardesty RL, Griffith BP, Starzl TE: Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery. Transplantation 1989;47:993-995.
101. Cummins D, Contreras M, Amin S, Halil O, Down-ham B, Yacoub MH: Red cell alloantibody develop-Iment associated with heart and lung transplantation. Transplantation 1995;59:1432-1435.
102. Casanueva M, Valdes MD, Ribera MC: Lack of alloimmunization to D antigen in D-negative immunosuppressed liver transplant recipients. Transfusion 1994;34:570-572.
103. Yuan S, Davis R, Lu Q, Goldfinger D, Ziman AF: Low risk of alloimmunization to the D antigen in D- orthotopic liver transplant recipients receiving D+ RBCs perioperatively. Transfusion 2008;48:2653-2655.
104. Frohn C, Dumbgen L, Brand JM, Gorg S, Luhm J, Kirchner H: Probability of anti-D development in D- patients receiving D+ RBCs. Transfusion 2003; 43:893-898.
105. Yazer MH, Triulzi DJ: Detection of anti-D in D- recipients transfused with D+ red blood cells. Trans-fusion 2007;47:2197-2201.
106. Gonzalez-Porras JR, Graciani IF, Perez-Simon JA, Martin-Sanchez J, Encinas C, Conde MP, Nieto MJ, Corral M: Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients. Transfusion 2008;48:1318-1324.
107. Yazer MH, Triulzi DJ: Receipt of older RBCs does not predispose D-negative recipients to anti-D alloimmunization. AmJ Clin Pathol 2010;134:443-447.
108. Heim MU, Bock M, Kolb HJ, Schleuning M, Mempel W: Intravenous anti-D gammaglobulin for the prevention of rhesus isoimmunization caused by platelet transfusions in patients with malignant diseases. Vox Sang 1992;62:165-168.
109. Pollack W, Gorman JG, Hager HJ, Freda VJ, Tripodi D: Antibody-mediated immune suppression to the Rh factor: animal models suggesting mechanism of action. Transfusion 1968;8:134-145.
110. Anderson B, Shad AT, Gootenberg JE, Sandler SG: Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin [WinRho SD). Am J Hematol 1999;60:245-247.
111. Bowman JM: The advantages of intravenous Rh-immune globulin. Clin Obstet Gynecol 1982;25: 341-347.